Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-21
2000-01-18
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 514 3, 514 4, 424520, 424537, A61K 3830
Patent
active
060157860
ABSTRACT:
Methods are provided for treating or alleviating the symptoms of subjects with psychological disorders, metabolic disorders, chronic stress-related disorders, sleep disorders, conditions associated with sexual senescence, aging, or premature aging by treating such subjects with IGF or mutant IGF either alone or complexed with IGFBP-3. Methods for increasing the levels of DHEA or DHEAS and treating or alleviating the symptoms of subjects with disorders characterized by low levels of DHEA or DHEAS by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are also provided. Methods for increasing the level of T4 and treating or alleviating the symptoms of subjects with disorders characterized by low levels of T3 or T4 by administering effective amounts of IGF or mutant IGF alone or complexed with IGFBP-3 are additionally provided.
REFERENCES:
patent: 4835147 (1989-05-01), Roberts
patent: 4988675 (1991-01-01), Froesch et al.
patent: 5068224 (1991-11-01), Fryklund et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5106832 (1992-04-01), Froesch et al.
patent: 5128320 (1992-07-01), Hahn et al.
patent: 5162198 (1992-11-01), Eich et al.
patent: 5187151 (1993-02-01), Clark et al.
patent: 5200509 (1993-04-01), Spencer et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5273961 (1993-12-01), Clark
patent: 5407684 (1995-04-01), Loria et al.
patent: 5407913 (1995-04-01), Sommer et al.
patent: 5407927 (1995-04-01), Morales et al.
patent: 5420112 (1995-05-01), Lewis et al.
patent: 5434134 (1995-07-01), Gluckman et al.
patent: 5527776 (1996-06-01), Carlino et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5534493 (1996-07-01), Gluckman et al.
patent: 5736515 (1998-04-01), Bengtsson et al.
Carroll et al., "The effect of growth hormone replacement on the biochemical, body composition and psychological profiles of deficient adults" Journal of Endocrinology 148:P252 (1996).
Flood et al., "Dehydroepiandrosterone and its sulfate enhance memory retention in mice" Chemical Abstracts 108(25):216528 (1988).
Hesse et al., "Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age" Exp. Clin. Endocrinol. 102(4):289-298 (1994).
Hussain et al., "Insulin-like growth factor-I alters peripheral thyroid hormone metabolism in humans: comparison with growth hormone" Eur J. Endocrinol. 134(5):563-567 (1996).
Huybrechts et al., "Effect of recombinant human insulin-like growth factor-I on weight gain, fat content and hormonal parameters in broiler chickens" Chemical Abstracts 116(15):150581 (1992).
Kuhn et al., "Insulin-like growth factor (IGF-1), IGF-binding protein III and growth hormone in major depression" Pharmacopsychiatry 28(5):195 (1995).
L'Allemand et al., "Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured humanadrenocortical cells" J. Clin Endocrinol. Metab. 81(11):3892-3897 (1996).
Miyamoto et al., "Effects of neurosteroids on the impaired memory retention of aged C57BL/6J mice" Database Embase, Elsevier Science Publishers, Amsterdam NL, Abs. Acess. No. 96314452.
Mooney et al., "Insulin-like growth factor (IGF-1) increases working memory in aged animals" Society for Neuroscience Abstracts 22(1-3):1237 (1996).
Pergola et al., "Insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulphate in obese women" Int. J. Obes. 17(8):481-483 (1993).
Trung et al., "Effects of insulin-like growth factor I (IGF-I) on enzymatic activity in human adrenocortical cells. Interactions with ACTH" J. Steroid Biochem. Mol. Biol. 39(6):903-909 (1991).
Wolkowitz et al., "Dehydroepiandrosterone (DHEA) treatment of depression" Database Medline, Abs. Access. No. 97177429.
Nathorst-Boos et al., "Elective ovarian removal and estrogen replacement therapy--effects on sexual life, psychological well-being and androgen status" J. Psychosom. Obstet. Gynaecol. (1993) 14:283-293.
Popp et al., "Hematology of a murine .beta.-thalasemia: A longitudinal study" The New York Acad. Sci. (1985) 445:432-444.
Resnicoff et al., "Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors" Cancer Res. (1994) 54:2218-2222.
Rinderknecht et al., "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: Isolation, chemical characterization, and some biological properties of forms I and II" Proc. Natl. Acad. Sci. USA (1976) 73:2365-2369.
Robel et al., Dehydroepiandrosterone (DHEA) is a neuroactive neurosteroid Ann. N.Y. Acad. Sci. (1995) 774:82-110.
Shetty et al., "Hyposomatomedinemia in quadriplegic men" Am. J. Med. Sci. (1993) 305:95-100.
Sommer et al., "Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3" Modern Concepts of Insulin-Like Growth Factors (1991) E.M. Spencer, ed., Elsevier, New York, pp. 715-728.
Tallis, Primary hypothyroidism: A case for vigilance in the psychological treatment of depression Brit. J. Clin. Psychol. (1993) 32:261-270.
Tsitouras et al., "Serum testosterone and growth hormone/insulin-like growth factor-1 in adults with spinal cord injury" Horm. Metab. Res. (1995) 27:287-292.
Wolfe et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia" Arthritis Rheum. (1990) 33:160-172.
Yang et al., "A mouse mode for .beta..sup. -thalassemia" Proc. Natl. Acad. Sci. USA (1995) 92:11608-11612.
Yasin et al., "Melatonin and its analogs inhibit the basal and stimulated release of hypothalamic vasopressin and oxytocin in vitro" Endocrinol. (1993) 132:1329-1336.
Zhou et al., "Exposure to physical and psychological stressors elevates plasma interleukin 6: Relationship to the activation of hypothalamic-pituitary-adrenal axis" Endocrinol. (1993) 133:2523-2530.
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition: DSM-IV.TM., American Psychiatric Association, Washington, D.C. Title page and table of contents.
Ferraccioli et al., "Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia" J. Rheumatol. (1994) 21:1332-1334.
Flood et al., "Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it" Proc. Natl. Acad. Sci. USA (1992) 89:1567-1571.
Flood et al., "Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: The amygdala is by far the most sensitive" Proc. Natl. Acad. Sci. USA (1995) 92:10806-10810.
Geders et al., "The effect of cisapride on segmental colonic transit time in patients with spinal cord injury" Am. J. Gastroenterol. (1995) 90:285-289.
Holsboer et al., "Steroid effects on central neurons and implications for psychiatric and neurological disorders" Ann. N.Y. Acad. Sci. (1994) 746:345-361.
Huang et al., "Suppression of the hypothalamus-pituitary somatotrope axis in men with spinal cord injuries" Metabolism (1995) 44:1116-1120.
Kahn et al., "Loss of high-affinity prostacyclin receptors in platelets and the lack of prostaglandin-induced inhibition of platelet-stimulated thrombin generation in subjects with spinal cord injury" Proc. Natl. Acad. Sci. USA (1996) 93:245-249.
Kamikubo et al., "Similar nuclear factors mediate stimulation of rat thyroglobulin gene transcription by thyrotropin and insulin-like growth factor-1" Mol. Endocrinol. (1990) 4:2021-2029.
Katagiri et al., "The role of cytochrome b.sub.5 in the biosynthesis of androgens by human P450c17" Arch. Biochem. Biophys. (1995) 317:343-347.
Moldofsky et al., "Musculoskeletal symptoms and non-REM sleep disturbance in patients with `Fibrositis Syndrome` and healthy subjects" Psychosom. Med. (1975) 37:341-351.
Mondadori et al., "Delayed emergence of effects of memory-enhancing drugs: Implications for the dynamics of long-term memory" Proc. Natl. Acad. Sci. USA (1994) 91:2041-2045.
Morales et al., "Effects of
Mascarenhas Desmond
Sanders Martin
Celtrix Pharmaceuticals Inc.
Moezie F. T.
LandOfFree
Method for increasing sex steroid levels using IGF or IGF/IGFBP- does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing sex steroid levels using IGF or IGF/IGFBP-, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing sex steroid levels using IGF or IGF/IGFBP- will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-563419